Alpha 2.0
Login Register
» Authors » Damien Le Du

Damien Le Du

Explore the profile of Damien Le Du including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 15
Citations 425
Followers 0
Related Specialties
Infectious Diseases
Pulmonary Medicine
Microbiology
Top 10 Co-Authors
Nicolas Veziris
Lorenzo Guglielmetti
Eric Caumes
Mathilde Frechet-Jachym
Jerome Robert
Dhiba Marigot-Outtandy
Yazdan Yazdanpanah
Christophe Rioux
Christine Bernard
Delia Goletti
Published In
Eur Respir J
J Infect
Clin Infect Dis
J Int Assoc Physicians AIDS Care (Chic)
Emerg Infect Dis
Affiliations
Soon will be listed here.
Recent Articles
1.
Association Between Increased Linezolid Plasma Concentrations and the Development of Severe Toxicity in Multidrug-Resistant Tuberculosis Treatment
Eimer J, Frechet-Jachym M, Le Du D, Caumes E, El-Helali N, Marigot-Outtandy D, et al.
Clin Infect Dis . 2022 Jun; 76(3):e947-e956. PMID: 35717636
Background: Treatment of multidrug-resistant (MDR) tuberculosis with linezolid is characterized by high rates of adverse events. Evidence on therapeutic drug monitoring to predict drug toxicity is scarce. This study aimed...
2.
Co-administration of treatment for rifampicin-resistant TB and chronic HCV infection: A TBnet and ESGMYC study
Tunesi S, Le Du D, Gualano G, Millet J, Skrahin A, Bothamley G, et al.
J Infect . 2022 Mar; 84(6):834-872. PMID: 35271917
No abstract available.
3.
Active tuberculosis, sequelae and COVID-19 co-infection: first cohort of 49 cases
Tadolini M, Codecasa L, Garcia-Garcia J, Blanc F, Borisov S, Alffenaar J, et al.
Eur Respir J . 2020 May; 56(1). PMID: 32457198
No abstract available.
4.
Safety and efficacy of exposure to bedaquiline-delamanid in multidrug-resistant tuberculosis: a case series from France and Latvia
Guglielmetti L, Barkane L, Le Du D, Marigot-Outtandy D, Robert J, Veziris N, et al.
Eur Respir J . 2018 Feb; 51(3). PMID: 29419439
No abstract available.
5.
Four-days-a-week antiretroviral maintenance therapy in virologically controlled HIV-1-infected adults: the ANRS 162-4D trial
De Truchis P, Assoumou L, Landman R, Mathez D, Le Du D, Bellet J, et al.
J Antimicrob Chemother . 2017 Nov; 73(3):738-747. PMID: 29186458
Background: Intermittent treatment could improve the convenience, tolerability and cost of ART, as well as patients' quality of life. We conducted a 48 week multicentre study of a 4-days-a-week antiretroviral...
6.
Long-term outcome and safety of prolonged bedaquiline treatment for multidrug-resistant tuberculosis
Guglielmetti L, Jaspard M, Le Du D, Lachatre M, Marigot-Outtandy D, Bernard C, et al.
Eur Respir J . 2017 Feb; 49(3). PMID: 28182570
Bedaquiline, a recently approved drug for the treatment of multidrug-resistant tuberculosis (MDR-TB), is recommended for a duration of 24 weeks. There are scarce data on patients treated with this drug...
7.
Rapid emergence of bedaquiline resistance: lessons to avoid repeating past errors
Veziris N, Bernard C, Guglielmetti L, Le Du D, Marigot-Outtandy D, Jaspard M, et al.
Eur Respir J . 2017 Feb; 49(3). PMID: 28182568
No abstract available.
8.
Visualizing viable Mycobacterium tuberculosis in sputum to monitor isolation measures
Wyplosz B, Mougari F, Al Rawi M, Baillon C, Marigot-Outtandy D, Le Du D, et al.
J Infect . 2016 Dec; 74(2):207-210. PMID: 27939814
No abstract available.
9.
Preventing Acquired Resistance to Bedaquiline and Delamanid in Multidrug-Resistant Tuberculosis Treatment Requires Optimal Management
Guglielmetti L, Le Du D, Frechet-Jachym M, Mitnick C
Am J Respir Crit Care Med . 2016 Nov; 194(9):1170-1171. PMID: 27797614
No abstract available.
10.
Is bedaquiline as effective as fluoroquinolones in the treatment of multidrug-resistant tuberculosis?
Guglielmetti L, Le Du D, Veziris N, Caumes E, Marigot-Outtandy D, Yazdanpanah Y, et al.
Eur Respir J . 2016 Jun; 48(2):582-5. PMID: 27338196
No abstract available.